secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acorda Therapeutics, Inc. (—)
CIK:        0001008848
Form:       8-K
Filed at:   2022-12-21T23:59:59+00:00
Accession:  0001193125-22-309544
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acorda Therapeutics faces Nasdaq delisting for bid price noncompliance; hearing requested
--------------------------------------------------------------------------------

- Nasdaq notified Acorda that common stock will be delisted on Dec 29, 2022 for failing to maintain $1 minimum bid price for 30 consecutive business days.
- Company had 180-day compliance period that ended Dec 19, 2022; did not regain compliance.
- Acorda will request a hearing within 7 days, which automatically stays delisting pending Panel decision.
- Hearings Panel may grant extension to regain compliance until June 17, 2023; company plans to present plan.
- Stockholders approved reverse stock split (1:2 to 1:20) in Nov 2022; CEO prefers organic growth but split is an option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1008848/000119312522309544/0001193125-22-309544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1008848/000119312522309544/d368917d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-309544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer